# Diabetic Gastroparesis Efficacy/Safety Study of TZP-102

> **NCT01664637** · PHASE2 · TERMINATED · sponsor: **Tranzyme, Inc.** · enrollment: 120 (estimated)

## Conditions studied

- Diabetic Gastroparesis

## Interventions

- **DRUG:** 10 mg TZP-102
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01664637
- **Lead sponsor:** Tranzyme, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-08
- **Primary completion:** 2013-01
- **Final completion:** 2013-02
- **Target enrollment:** 120 (ESTIMATED)
- **Why stopped:** Insufficient efficacy in planned interim futility analysis
- **Last updated:** 2012-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01664637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01664637, "Diabetic Gastroparesis Efficacy/Safety Study of TZP-102". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01664637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*